COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

By Dr Allison Barraclough, who trained and worked in WA before recently relocating to Melbourne, and several collaborating co-authors (including four from Western Australia), which looked into gene-expression profiling and prognosis for patients with stage I/II Diffuse Large B-Cell Lymphoma (DLBCL).

211 patients were identified for this retrospective study across Sir Charles Gairdner Hospital, Hollywood Private Hospital, Princess Alexandra Hospital, British Columbia Centre for Lymphoid Cancer, Aalborg University Hospital, and Nottingham University Hospital.

Key points of note:

• In early-stage DLBCL, COO and DE/DH [gene expression] status may not confer an inferior prognosis.
• Stage I/II DLBCL has an excellent outcome when treated with R-CHOP–like therapy ± radiation, with 4-year Progression Free Survival and Overall Survival rates of 85% and 88%.

The full article can be viewed here: http://www.bloodadvances.org/content/3/13/2013?sso-checked=true